| Market Capitalization (Millions $) |
12 |
| Shares
Outstanding (Millions) |
65 |
| Employees |
87 |
| Revenues (TTM) (Millions $) |
1 |
| Net Income (TTM) (Millions $) |
-91 |
| Cash Flow (TTM) (Millions $) |
-20 |
| Capital Exp. (TTM) (Millions $) |
2 |
Lyra Therapeutics Inc
Lyra Therapeutics Inc. is a biotechnology company that focuses on developing novel therapies for ear, nose, and throat (ENT) conditions. The company's main expertise lies in the field of localized drug delivery, specifically using its proprietary Xtampza' technology platform.
Lyra Therapeutics aims to provide effective treatment options for various ENT conditions, including chronic rhinosinusitis (CRS). Their Xtampza technology enables the controlled and sustained release of therapeutics directly to the affected areas, allowing for localized and long-lasting drug delivery.
By utilizing their innovative approach, Lyra Therapeutics aims to improve patient outcomes and address the limitations of existing treatments for ENT conditions. Their research and development efforts are focused on advancing the clinical development of their pipeline products, with the ultimate goal of bringing novel therapies to patients in need.
Company Address: 480 Arsenal Way Watertown 2472 MA
Company Phone Number: 393-4600 Stock Exchange / Ticker: NASDAQ LYRA
|
